Micofenolato De Mofetil Generis (Mycophenolate Mofetil)

Mycophenolate Mofetil selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for de novo guanosine nucleotide synthesis. This inhibition limits the proliferation of activated T‑ and B‑lymphocytes, thereby dampening the immune response that can lead to organ rejection or autoimmune kidney damage.

The specific dose of Micofenolato De Mofetil Generis is determined by the prescribing clinician based on the patient’s condition, weight, renal function and other individual factors. Healthcare professionals set the appropriate regimen and adjust it as needed during therapy.

Mycophenolate Mofetil is classified as Pregnancy Category D because it can cause fetal malformations and pregnancy loss. It is contraindicated in pregnant women and should be stopped before conception. Breastfeeding is not recommended, as the drug is excreted in milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Mycophenolate Mofetil differs from calcineurin inhibitors such as cyclosporine or tacrolimus by targeting nucleotide synthesis rather than calcium‑dependent signaling. Compared with azathioprine, it offers more selective inhibition of lymphocyte proliferation and often a lower incidence of certain toxicities, though all agents require careful monitoring for infection and bone‑marrow suppression.

Micofenolato De Mofetil Generis should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product in a dry place and avoid exposure to extreme heat or humidity.

The medication is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and should not alter the regimen without medical advice.

Serious risks include profound leukopenia or neutropenia, which can predispose to severe infections, hepatotoxicity manifested by elevated liver enzymes or liver injury, and teratogenic effects leading to fetal malformations or miscarriage. Prompt reporting of fever, signs of infection or abnormal laboratory results is essential.

Patients with known hypersensitivity to Mycophenolate Mofetil or any component of the formulation should avoid the product. It is also contraindicated in pregnant women, women planning pregnancy, and in individuals with severe uncontrolled infections. Caution is advised in patients with significant renal or hepatic impairment.